

# HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM

### LONG-ACTING TACROLIMUS

Astagraf XL®, Envarsus XR®

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance 385-425-5094.

Disclaimer: Prior authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

**Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.**

**Product being request:** ☐ Astagraf XL® (tacrolimus extended-release), ☐ Envarsus XR® (tacrolimus extended-release)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Will tacrolimus extended-release be used for the prevention of organ rejection in a kidney transplant recipient?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Will tacrolimus extended-release be in used in combination with other immunosuppressants?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Is the requesting provider a nephrologist or transplant specialist?	<input type="checkbox"/>	<input type="checkbox"/>	
4. Is the member on a stable dose of tacrolimus immediate release with whole blood trough concentrations at goal?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Does the member have challenges with compliance and/or side effects with taking tacrolimus immediate-release	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

#### REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 6 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the therapy shown to be tolerable and effective with an improvement or stabilization in condition?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

**What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.**

Additional information:

Physician's Signature:

**\*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy: PHARM-CHIP-043

Origination Date: 07/01/2024

Reviewed/Revised Date: 06/11/2025

Next Review Date: 06/11/2026

Current Effective Date: 07/01/2025

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.